Royalty Pharma plc [RPRX] stock is trading at $35.27, up 3.58%. In order to assess the stock’s recent performance, you can check whether its short-term value is rising or falling. The RPRX shares have gain 4.50% over the last week, with a monthly amount glided 7.46%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Royalty Pharma plc [NASDAQ: RPRX] stock has seen the most recent analyst activity on May 16, 2025, when Morgan Stanley initiated its Overweight rating and assigned the stock a price target of $51. Previously, UBS downgraded its rating to Neutral on June 03, 2024, and kept the price target unchanged to $28. Scotiabank started tracking the stock assigning a Sector Outperform rating and suggested a price target of $53 on May 13, 2022. Goldman initiated its recommendation with a Buy and recommended $56 as its price target on April 27, 2022. JP Morgan upgraded its rating to Overweight for this stock on April 14, 2022, but kept the price target unchanged to $50.
Royalty Pharma plc [RPRX] stock has fluctuated between $24.05 and $34.31 over the past year. Currently, Wall Street analysts expect the stock to reach $43.33 within the next 12 months. Royalty Pharma plc [NASDAQ: RPRX] shares were valued at $35.27 at the most recent close of the market. An investor can expect a potential return of 22.85% based on the average RPRX price forecast.
Analyzing the RPRX fundamentals
Royalty Pharma plc [NASDAQ:RPRX] reported sales of 2.26B for the trailing twelve months, which represents a growth of 0.05%. Gross Profit Margin for this corporation currently stands at 1.0% with Operating Profit Margin at 0.84%, Pretax Profit Margin comes in at 0.78%, and Net Profit Margin reading is 0.48%. To continue investigating profitability, this company’s Return on Assets is posted at 0.06, Equity is 0.16 and Total Capital is 0.12. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 1.14.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance.
Ratios To Look Out For
For context, Royalty Pharma plc’s Current Ratio is 1.56. In addition, the Quick Ratio stands at 1.56 and the Cash Ratio stands at 0.92. Considering the valuation of this stock, the price to sales ratio is 8.76, the price to book ratio is 2.24 and price to earnings (TTM) ratio is 14.38.
